Gaxos.ai Inc. — Third Quarter 2026 Earnings Summary

Financial Performance:

• Consolidated revenue reached approximately $2.81 million, representing a 14.5% sequential increase from $2.46 million in Q2 2026 and a 464.9% year-over-year increase from $0.50 million in Q3 2025.
• Basic and diluted net loss per common share was $0.08 in Q3 2026, an improvement from $0.14 in Q3 2025.
• Advertising and marketing expense totaled approximately $2.62 million, a 16.7% decrease from $3.14 million in Q2 2026.
• Revenue per dollar of advertising and marketing expense improved to approximately $1.08 in Q3 2026, up from $0.78 in Q2 2026, marking a 38% improvement.
• Advertising and marketing expense represented 93% of consolidated revenue in Q3 2026, down from 128% in Q2 2026.
• Cash and short-term investments stood at approximately $13.30 million as of September 30, 2026, up from $11.44 million as of June 30, 2026.
• The Company received approximately $3.17 million in net proceeds from warrant exercises during the quarter, issuing 3,007,654 shares of common stock.

Guidance and Future Outlook:

• For the remainder of 2026, Gaxos intends to focus on increasing recurring and repeat revenue across its core operating businesses.
• Strategic priorities include improving customer-acquisition efficiency and advertising payback.
• The Company plans to scale products and customer channels that demonstrate favorable contribution economics.
• Management aims to maintain discipline in operating expenditures and capital allocation.
• Gaxos intends to provide investors with additional operating measurements where reliable and appropriate.

Business Segments and Product Lines:

• The Company operates through Gaxos Labs, which develops and commercializes AI-powered applications.
• Operations include RNK Health, a majority-owned subsidiary offering personalized weight loss, longevity, and performance treatments.
• Gaxos holds a strategic minority investment in America First Defense.AI, a defense-technology company developing next-generation counter-UAS and robotic platforms.

Other Key Points:

• The Company did not issue shares through its at-the-market offering program during the quarter ended September 30, 2026.
• As of November 11, 2026, the Company had 13,752,288 shares of common stock outstanding.
• Full details regarding the quarter's results are available in the Form 10-Q filed with the SEC.